BOSTON SCIENTIFIC CORP (BSX.DE) Stock Price, Forecast & Analysis

Europe • Frankfurt Stock Exchange • FRA:BSX • US1011371077

63 EUR
+0.4 (+0.64%)
Last: Feb 10, 2026, 07:00 PM

BSX.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap93.39B
Revenue(TTM)N/A
Net Income(TTM)2.79B
Shares1.48B
Float1.48B
52 Week High102
52 Week Low62
Yearly Dividend0
Dividend Yield0%
EPS(TTM)2.56
PE24.61
Fwd PE21.39
Earnings (Next)04-21
IPO1992-05-19
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
BSX.DE short term performance overview.The bars show the price performance of BSX.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20 -25

BSX.DE long term performance overview.The bars show the price performance of BSX.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40

The current stock price of BSX.DE is 63 EUR. In the past month the price decreased by -23.54%. In the past year, price decreased by -37.62%.

BOSTON SCIENTIFIC CORP / BSX Daily stock chart

BSX.DE Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
BSX.DE Full Technical Analysis Report

BSX.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE. Both the profitability and the financial health of BSX.DE get a neutral evaluation. Nothing too spectacular is happening here.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BSX.DE Full Fundamental Analysis Report

BSX.DE Financial Highlights

Over the last trailing twelve months BSX.DE reported a non-GAAP Earnings per Share(EPS) of 2.56. The EPS increased by 21.51% compared to the year before.


Industry RankSector Rank
PM (TTM) 14.42%
ROA 6.54%
ROE 11.93%
Debt/Equity 0.48
Chartmill High Growth Momentum
EPS Q2Q%14.29%
Sales Q2Q%15.9%
EPS 1Y (TTM)21.51%
Revenue 1Y (TTM)N/A
BSX.DE financials

BSX.DE Forecast & Estimates

40 analysts have analysed BSX.DE and the average price target is 107.92 EUR. This implies a price increase of 71.3% is expected in the next year compared to the current price of 63.

For the next year, analysts expect an EPS growth of 14.83% and a revenue growth 11.42% for BSX.DE


Analysts
Analysts85.5
Price Target107.92 (71.3%)
EPS Next Y14.83%
Revenue Next Year11.42%
BSX.DE Analyst EstimatesBSX.DE Analyst Ratings

BSX.DE Ownership

Ownership
Inst Owners94.07%
Ins Owners0.15%
Short Float %N/A
Short RatioN/A
BSX.DE Ownership

BSX.DE Competitors/Peers

The largest stocks on the EU markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
2M6 MEDTRONIC PLC16.59110.612B
SHL SIEMENS HEALTHINEERS AG17.0746.09B
PHIA KONINKLIJKE PHILIPS NV17.5626.548B
PHI1 KONINKLIJKE PHILIPS NV18.1226.548B
BIM BIOMERIEUX18.5811.167B
DIA DIASORIN SPA18.184.171B
OBCK OTTOBOCK SE & CO KGAA18.363.759B
AFX CARL ZEISS MEDITEC AG - BR11.842.522B
DRW3 DRAEGERWERK AG - PREF11.931.665B
DRW8 DRAEGERWERK AG9.591.328B

About BSX.DE

Company Profile

BSX logo image Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.

Company Info

BOSTON SCIENTIFIC CORP

300 Boston Scientific Way

Marlborough MASSACHUSETTS US

Employees: 53000

BSX Company Website

BSX Investor Relations

Phone: 13026365400

BOSTON SCIENTIFIC CORP / BSX.DE FAQ

What does BOSTON SCIENTIFIC CORP do?

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.


What is the current price of BSX stock?

The current stock price of BSX.DE is 63 EUR. The price increased by 0.64% in the last trading session.


Does BOSTON SCIENTIFIC CORP pay dividends?

BSX.DE does not pay a dividend.


What is the ChartMill rating of BOSTON SCIENTIFIC CORP stock?

BSX.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


What is the employee count for BSX stock?

BOSTON SCIENTIFIC CORP (BSX.DE) currently has 53000 employees.